This paper, produced by the International Myeloma Working Group (IMWG), provides an updated definition of high-risk myeloma based on cytogenetics and provides recommendations for the optimum treatment for this group of myeloma patients.
This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the management of patients with relapsed myeloma.
This paper by the International Myeloma Working Group, reviews the available evidence and provides recommendations for the management of myeloma-related kidney disease
These guidelines, produced by an expert panel on behalf of the European Myeloma Network (EMN), provide recommendations for the management of the most common complications of myeloma, including bone and kidney disease.
Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…
Advances in the Treatment of Paraproteinemic Neuropathy. Nobile-Orazio E et al. Curr Treat Options Neurol. 2017 Oct 16;19(12):43. doi: 10.1007/s11940-017-0479-9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363. doi: 10.1159/000481461. [Epub ahead of print]. Interbody distraction and vertebral body reconstruction with polymethylmethacrylate for the treatment of pathological…
A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Martino M et al. Biol Blood Marrow Transplant. 2017 Oct 12. pii: S1083-8791(17)30764-4. doi: 10.1016/j.bbmt.2017.09.021. [Epub ahead of print]. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the…
Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. Satin U et al. J Clin Apher. 2017 Oct 5. doi: 10.1002/jca.21591. [Epub ahead of print]. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Jeker B et al. Bone Marrow Transplant. 2017 Oct 23. doi: 10.1038/bmt.2017.234. [Epub ahead of print]. Phase II…
A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands. Cracolici V et al. Head Neck Pathol. 2017 Oct 13. doi: 10.1007/s12105-017-0861-7. [Epub ahead of print]. Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy. Nakae Y et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.9096-17. [Epub ahead of print].…
Amgen has announced that its Phase III trial, ARROW, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared the effect of giving patients a higher dose of carfilzomib (Kyprolis®) once a week, compared to a smaller dose twice a week, together with dexamethasone. The…